Thus, the measurement of circulating vesicular Cx26 in IHD patients may help clarify its potential as a biomarker for cardiomyocyte injury in cardiomyopathies with oxidative stress and apoptosis, including ischemic heart disease (IHD) and heart failure (HF). This evidence concerns the gene GJB2 and heart failure.